A PHASE I/II, RANDOMISED, OBSERVER-BLIND, CONTROLLED MULTI-COUNTRY STUDY TO ASSESS THE SAFETY, REACTOGENICITY AND IMMUNOGENICITY OF A SINGLE INTRAMUSCULAR DOSE OF GSK BIOLOGICALS' INVESTIGATIONAL RSV VACCINE (GSK3003891A), IN HEALTHY PREGNANT WOMEN AGED 18 TO 40 YEARS AND INFANTS BORN TO VACCINATED MOTHERS

Registry ID
204810 (RSV F-004)
Source registry
HEALTH_CANADA
Status
Pending
Phase
PHASE1
Study type
INTERVENTIONAL
Sponsor
GLAXOSMITHKLINE INC
Last update
2017-03-01

Conditions

Related clinical trials

View on source registry